Skip to main content

Table 3 Adverse treatments events

From: Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis

Adverse events

Number (proportion%)

Grade 1–2, n (proportion%)

Grade 3, n (proportion%)

Grade 4, n (proportion%)

Abdominal pain

26 (48.1)

26 (48.1)

0 (0)

0 (0)

Fever

23 (42.6)

23 (42.6)

0 (0)

0 (0)

Vomiting

7 (13.0)

7 (13.0)

0 (0)

0 (0)

Ascites

6 (11.1)

6 (11.1)

0 (0)

0 (0)

Pleural effusion

5 (9.3)

5 (9.3)

0 (0)

0 (0)

TBILa increase

28 (81.5)

28 (51.9)

16 (29.6)

0 (0)

ALTb increase

15 (27.8)

10 (18.5)

5 (9.3)

0 (0)

Hypoalbuminemia

43 (79.6)

43 (79.6)

0 (0)

0 (0)

Inguinal hematoma

0 (0)

0 (0)

0 (0)

0 (0)

Gastrointestinal bleeding

0 (0)

0 (0)

0 (0)

0 (0)

Pulmonary embolism

0 (0)

0 (0)

0 (0)

0 (0)

Primary peritonitis

2 (3.7)

0 (0)

2 (3.7)

0 (0)

  1. aTBIL total bilirubin
  2. bALT alanine aminotransferase